.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR20_EmtricitabineTenofovirAlafenamid.EmtricitabineTenofovirAlafenamid .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR20_EmtricitabineTenofovirAlafenamid.EmtricitabineTenofovirAlafenamid| name: | EmtricitabineTenofovirAlafenamideAndBictegravir |
| ATC code: | J05AR20 | route: | oral |
| n-compartments | 1 |
Emtricitabine, tenofovir alafenamide, and bictegravir is a fixed-dose combination antiretroviral medication used in the treatment of HIV-1 infection in adults and pediatric patients. It acts by inhibiting viral reverse transcriptase (emtricitabine, tenofovir) and integrase (bictegravir), preventing the replication of HIV-1. The combination is approved and widely used today.
Mean pharmacokinetic parameters reported for healthy HIV-negative adult subjects receiving the fixed-dose combination as a single oral tablet once daily under fasting conditions.
Bruzzesi, E, et al., & Castagna, A (2024). Pharmacokinetic evaluation of bictegravir + emtricitabine + tenofovir alafenamide in HIV treatment. Expert opinion on drug metabolism & toxicology None 1–8. DOI:10.1080/17425255.2024.2428820 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39530796